Plain-English translation of NCT05041153 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This early-phase trial is testing a combination of two medications— and —to see if they can help people with advanced stomach or gastroesophageal cancer whose disease has progressed despite previous treatment. works by helping your immune system recognize and attack cancer cells, while blocks signals that allow tumors to grow. The study will measure how many patients respond to this treatment combination and track how well and how safely it works.
Advanced stomach cancer is difficult to treat once it has spread or cannot be surgically removed, and many patients do not respond well to standard options. Researchers believe combining these two types of medication—one that boosts immunity and one that slows tumor growth—might be more effective than treatments available today.
You will receive as an intravenous infusion (into a vein) over 30 minutes on day 1 of each treatment cycle, and you will take as a daily oral tablet. Each treatment cycle lasts 42 days (about 6 weeks), and you may continue this combination for up to 17 cycles as long as your disease does not progress and you tolerate the medication well. You will have regular clinic visits for blood tests, imaging scans to assess your tumor response, and monitoring for side effects; after treatment ends, you will be followed up at 30 days and then every 12 weeks.
AI-generated summary from trial data · Jul 19, 2026 · Not medical advice
United States